



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Cilgavimab

Cat. No.:	HY-P99604
CAS No.:	2420563-99-9
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection ^[1] .
IC₅₀ & Target	SARS-CoV-2 ^{[1][2]}
In Vitro	Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potentially neutralize the virus ^[1] . Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC ₅₀ s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC ₅₀ s of 0.1-10 ng/mL ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Cilgavimab (200 µg/mouse; i.p.; before SARS-CoV-2 injection) protects mice from weight loss and reduces the viral burden and levels of inflammation in the lungs ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200.
- [2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA